BIOMAT Database Logo BIOMAT Database Logo

Design and synthesis of potent RSK inhibitors. 2018

Rama Jain, and Michelle Mathur, and Jiong Lan, and Abran Costales, and Gordana Atallah, and Savithri Ramurthy, and Sharadha Subramanian, and Lina Setti, and Paul Feucht, and Bob Warne, and Laura Doyle, and Stephen Basham, and Anne B Jefferson, and Brent A Appleton, and Mika Lindvall, and Cynthia M Shafer
Global Discovery Chemistry/Oncology & Exploratory Chemistry, Novartis Institutes for Biomedical Research, 5300 Chiron Way, Emeryville, CA 94608, United States.

Utilizing the already described 3,4-bi-aryl pyridine series as a starting point, incorporation of a second ring system with a hydrogen bond donor and additional hydrophobic contacts yielded the azaindole series which exhibited potent, picomolar RSK2 inhibition and the most potent in vitro target modulation seen thus far for a RSK inhibitor. In the context of the more potent core, several changes at the phenol moiety were assessed to potentially find a tool molecule appropriate for in vivo evaluation.

UI MeSH Term Description Entries
D010636 Phenols Benzene derivatives that include one or more hydroxyl groups attached to the ring structure.
D002853 Chromatography, Liquid Chromatographic techniques in which the mobile phase is a liquid. Liquid Chromatography
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013058 Mass Spectrometry An analytical method used in determining the identity of a chemical based on its mass using mass analyzers/mass spectrometers. Mass Spectroscopy,Spectrometry, Mass,Spectroscopy, Mass,Spectrum Analysis, Mass,Analysis, Mass Spectrum,Mass Spectrum Analysis,Analyses, Mass Spectrum,Mass Spectrum Analyses,Spectrum Analyses, Mass
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D047428 Protein Kinase Inhibitors Agents that inhibit PROTEIN KINASES. Protein Kinase Inhibitor,Inhibitor, Protein Kinase,Inhibitors, Protein Kinase,Kinase Inhibitor, Protein,Kinase Inhibitors, Protein
D066244 Proton Magnetic Resonance Spectroscopy Spectroscopy technique which measures changes in organic compounds by tracking the spectral energy of absorption of HYDROGEN atoms. 1H NMR,1H-MRS,1H-NMR

Related Publications

Rama Jain, and Michelle Mathur, and Jiong Lan, and Abran Costales, and Gordana Atallah, and Savithri Ramurthy, and Sharadha Subramanian, and Lina Setti, and Paul Feucht, and Bob Warne, and Laura Doyle, and Stephen Basham, and Anne B Jefferson, and Brent A Appleton, and Mika Lindvall, and Cynthia M Shafer
Design, synthesis and anti-breast cancer evaluation of biaryl pyridine analogues as potent RSK inhibitors.
March 2022, Bioorganic & medicinal chemistry letters,
Rama Jain, and Michelle Mathur, and Jiong Lan, and Abran Costales, and Gordana Atallah, and Savithri Ramurthy, and Sharadha Subramanian, and Lina Setti, and Paul Feucht, and Bob Warne, and Laura Doyle, and Stephen Basham, and Anne B Jefferson, and Brent A Appleton, and Mika Lindvall, and Cynthia M Shafer
Design and synthesis of potent macrocyclic renin inhibitors.
January 2011, Bioorganic & medicinal chemistry letters,
Rama Jain, and Michelle Mathur, and Jiong Lan, and Abran Costales, and Gordana Atallah, and Savithri Ramurthy, and Sharadha Subramanian, and Lina Setti, and Paul Feucht, and Bob Warne, and Laura Doyle, and Stephen Basham, and Anne B Jefferson, and Brent A Appleton, and Mika Lindvall, and Cynthia M Shafer
Design and synthesis of potent, selective inhibitors of matriptase.
July 2012, ACS medicinal chemistry letters,
Rama Jain, and Michelle Mathur, and Jiong Lan, and Abran Costales, and Gordana Atallah, and Savithri Ramurthy, and Sharadha Subramanian, and Lina Setti, and Paul Feucht, and Bob Warne, and Laura Doyle, and Stephen Basham, and Anne B Jefferson, and Brent A Appleton, and Mika Lindvall, and Cynthia M Shafer
Synthesis of a potent and selective inhibitor of p90 Rsk.
March 2005, Organic letters,
Rama Jain, and Michelle Mathur, and Jiong Lan, and Abran Costales, and Gordana Atallah, and Savithri Ramurthy, and Sharadha Subramanian, and Lina Setti, and Paul Feucht, and Bob Warne, and Laura Doyle, and Stephen Basham, and Anne B Jefferson, and Brent A Appleton, and Mika Lindvall, and Cynthia M Shafer
Design, synthesis and biological evaluation of potent FAAH inhibitors.
June 2016, Bioorganic & medicinal chemistry letters,
Rama Jain, and Michelle Mathur, and Jiong Lan, and Abran Costales, and Gordana Atallah, and Savithri Ramurthy, and Sharadha Subramanian, and Lina Setti, and Paul Feucht, and Bob Warne, and Laura Doyle, and Stephen Basham, and Anne B Jefferson, and Brent A Appleton, and Mika Lindvall, and Cynthia M Shafer
Design and synthesis of potent, isoxazole-containing renin inhibitors.
April 2012, Bioorganic & medicinal chemistry letters,
Rama Jain, and Michelle Mathur, and Jiong Lan, and Abran Costales, and Gordana Atallah, and Savithri Ramurthy, and Sharadha Subramanian, and Lina Setti, and Paul Feucht, and Bob Warne, and Laura Doyle, and Stephen Basham, and Anne B Jefferson, and Brent A Appleton, and Mika Lindvall, and Cynthia M Shafer
Design and synthesis of potent and selective macrocyclic thrombin inhibitors.
August 2003, Bioorganic & medicinal chemistry letters,
Rama Jain, and Michelle Mathur, and Jiong Lan, and Abran Costales, and Gordana Atallah, and Savithri Ramurthy, and Sharadha Subramanian, and Lina Setti, and Paul Feucht, and Bob Warne, and Laura Doyle, and Stephen Basham, and Anne B Jefferson, and Brent A Appleton, and Mika Lindvall, and Cynthia M Shafer
Design and synthesis of potent and selective BACE-1 inhibitors.
February 2010, Journal of medicinal chemistry,
Rama Jain, and Michelle Mathur, and Jiong Lan, and Abran Costales, and Gordana Atallah, and Savithri Ramurthy, and Sharadha Subramanian, and Lina Setti, and Paul Feucht, and Bob Warne, and Laura Doyle, and Stephen Basham, and Anne B Jefferson, and Brent A Appleton, and Mika Lindvall, and Cynthia M Shafer
Design and synthesis of potent and highly selective thrombin inhibitors.
November 1994, Journal of medicinal chemistry,
Rama Jain, and Michelle Mathur, and Jiong Lan, and Abran Costales, and Gordana Atallah, and Savithri Ramurthy, and Sharadha Subramanian, and Lina Setti, and Paul Feucht, and Bob Warne, and Laura Doyle, and Stephen Basham, and Anne B Jefferson, and Brent A Appleton, and Mika Lindvall, and Cynthia M Shafer
Design and Synthesis of Highly Potent and Specific ABHD6 Inhibitors.
November 2023, ChemMedChem,
Copied contents to your clipboard!